Ocular Therapeutix, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-265.9M | $-193.5M | $-80.7M | $-71.0M | $-6.6M | $-155.6M | $-86.4M | $-60.0M |
| Depreciation & Amortization | $4.3M | $3.8M | $3.0M | $2.1M | $2.4M | $2.8M | $2.5M | $2.3M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $43.2M | $33.1M | $17.8M | $17.0M | $15.0M | $7.5M | $8.8M | $7.5M |
| Net Cash from Operating Activities | $-204.9M | $-134.7M | $-70.2M | $-59.6M | $-65.6M | $-53.6M | $-77.6M | $-49.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $12.0M | $1.3M | $6.1M | $3.7M | $1.2M | $841.0K | $2.2M | $1.9M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-11.9M | $-1.3M | $-6.1M | $-3.7M | $-1.2M | $-841.0K | $-2.2M | $-1.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $561.7M | $332.1M | $169.8M | $1.5M | $2.9M | $228.0M | $75.3M | $68.6M |
| Net Change in Cash | $345.0M | $196.1M | $93.5M | $-61.9M | $-63.9M | $173.6M | $-4.5M | $17.5M |
| Free Cash Flow | $-216.9M | $-136.0M | $-76.3M | $-63.3M | $-66.7M | $-54.4M | $-79.8M | $-51.1M |